



KNOWLEDGE, ATTITUDE AND PRACTICES OF PHOSPHATE BINDERS IN CHRONIC KIDNEY DISEASE PATIENTS : A COMPREHENSIVE REVIEW

¹AL-AMAL A S, ²Dr NITHIN MANOHAR R, ³Dr PADMESH P R, ⁴Dr PRASOBH G R, ¹P N POOJA,
¹ADSHAYA A R, ¹ANJANA RANI R.

1. Fifth Year Student, Doctor Of Pharmacy, Sree Krishna College Of Pharmacy And Research Centre, Parassala Thiruvananthapuram, Kerala, India.
2. Professor & HOD, Department of Pharmacy Practice, Sree Krishna college of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India.
3. Assistant Professor, Department of Pharmacy Practice, Sree Krishna college of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India.
4. Principal, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India.

Abstract: Chronic Kidney Disease (CKD) poses a global health challenge, with hyperphosphatemia emerging as a critical contributor to disease progression. Phosphate binders play a pivotal role in CKD management, however their effectiveness is intricately tied to the knowledge, attitudes, and practices of both patients and healthcare providers. This comprehensive review synthesizes the existing literature to explore the multifaceted landscape of phosphate binder utilization in CKD. The mechanisms of action, types, and importance of phosphate binders are delineated, providing a foundation for understanding their role in clinical practice. Analysis of patient awareness reveals that targeted educational interventions not only increase patients' knowledge, but also significantly improve adherence to prescribed phosphate binder regimens. Discrepancies in healthcare provider knowledge underscore the necessity for continuous education to align practices with evolving evidence. Patient and healthcare provider attitudes significantly influence prescribing practices, emphasizing the need for tailored interventions. Examination of current practices reveals barriers to adherence and the importance of interdisciplinary collaboration. The review identifies gaps in knowledge, challenges in attitude, and future directions, emphasizing the potential of technology and collaborative care models. In conclusion, optimizing phosphate binder therapy in CKD necessitates a comprehensive approach addressing knowledge gaps, fostering positive attitudes, and refining clinical practices. Continuous efforts in research and education are pivotal for advancing CKD management and improving patient outcomes.

Keywords: CKD, Hyperphosphatemia, phosphate binders, patient education, KAP.

1. Introduction

Chronic Kidney Disease (CKD) poses a significant global health challenge, affecting millions of individuals worldwide ⁽¹⁾. Among the various complications associated with CKD, hyperphosphatemia stands out as a critical factor contributing to disease progression ⁽²⁾. Phosphate binders have emerged as cornerstone therapeutic agents in managing elevated phosphate levels in CKD patients ⁽³⁾. This comprehensive review aims to delve into the intricate interplay of knowledge, attitude, and practices surrounding phosphate binders within the CKD population. By synthesizing existing literature, this article seeks to provide valuable insights into the current landscape of patient and healthcare provider perspectives, offering a foundation for optimizing the management of hyperphosphatemia in CKD.

2. Phosphate Binders in CKD

2.1 Mechanism of Action: Phosphate binders play a pivotal role in CKD management by mitigating the absorption of dietary phosphate within the gastrointestinal tract ⁽⁴⁾. Calcium-based binders, such as calcium carbonate and calcium acetate, act by forming insoluble complexes with dietary phosphate, preventing its absorption ⁽²¹⁾. Non-calcium-based binders, including sevelamer and lanthanum carbonate, offer alternatives to address concerns related to vascular calcification associated with calcium-based agents ⁽⁴⁾. Understanding the distinct mechanisms of action of these binders is crucial in tailoring treatment strategies for individual CKD patients.

2.2 Importance in CKD Management: Controlling phosphate levels is essential in CKD to mitigate the risk of mineral and bone disorders, cardiovascular complications, and overall disease progression ⁽⁶⁾. Phosphate binders serve as key components in achieving and maintaining phosphate homeostasis, thereby contributing to the comprehensive care of CKD patients. The efficacy of these agents in preventing complications underscores their significance in the broader context of CKD management.

2.3 Types of Phosphate Binders: Phosphate binders are categorized into calcium-based and non-calcium-based agents, each with its advantages and potential drawbacks ⁽⁷⁾. Calcium-based binders, while effective, may contribute to hypercalcemia and vascular calcification, necessitating careful consideration of their use ⁽⁸⁾. Non-calcium-based binders offer alternatives with potential cardiovascular benefits, emphasizing the importance of personalized therapeutic approaches. Awareness of these distinctions is vital for healthcare providers when tailoring treatment regimens for CKD patients.

3. Knowledge of Phosphate Binders

3.1 Patient Awareness: Patients' awareness of phosphate binders is a crucial aspect of successful management ⁽¹⁰⁾. Recent studies have shown that targeted educational interventions not only increase patients' knowledge but also significantly improve adherence to prescribed phosphate binder regimens ⁽¹¹⁾. Addressing specific patient concerns, such as potential side effects and dietary restrictions, within educational programs enhances the overall comprehension of phosphate binder therapy ⁽¹²⁾.

3.2 Healthcare Provider Knowledge: Variations in healthcare provider knowledge regarding phosphate binders have been documented, indicating the need for ongoing education and training ⁽¹³⁾. A study by Johnson et al. highlighted the impact of educational interventions for healthcare providers, leading to improved understanding of phosphate binder mechanisms and appropriate prescribing practices ⁽¹⁴⁾. Implementing structured educational programs for clinicians ensures that they stay abreast of the latest developments in phosphate binder therapy.

3.3 Adherence and Patient Outcomes: Knowledge about phosphate binders is directly linked to patient adherence, and improved adherence is associated with better clinical outcomes ⁽¹⁵⁾. Research by Smith et al. demonstrated a positive correlation between patient knowledge, adherence to prescribed phosphate binders,

and better phosphate control ⁽¹⁶⁾. Understanding the connection between knowledge, adherence, and outcomes emphasizes the need for comprehensive patient education strategies that go beyond imparting basic information.

3.4 Impact of Cultural Competence: Cultural competence plays a pivotal role in patient education and knowledge acquisition ⁽¹⁷⁾. Studies, such as that conducted by Ramirez et al., have shown that tailoring educational materials to specific cultural contexts enhances patient understanding and engagement with phosphate binder therapy ⁽¹⁸⁾. Recognizing cultural nuances ensures that information is effectively communicated and promotes a more patient-centered approach to knowledge dissemination.

4. Attitude Towards Phosphate Binders

4.1 Patient Perspectives: Understanding patient attitudes towards phosphate binders is paramount for optimizing adherence ⁽¹⁹⁾. Recent findings suggest that patients often perceive the efficacy of phosphate binders positively, recognizing their role in managing CKD complications ⁽²⁰⁾. However, concerns and misconceptions regarding potential side effects may influence attitudes and impact medication adherence ⁽²¹⁾. Tailoring interventions to address these concerns can foster a more positive attitude towards phosphate binder therapy.

4.2 Healthcare Provider Attitudes: Healthcare providers' attitudes significantly influence prescribing practices ⁽²²⁾. Studies reveal challenges in prescribing patterns, with some clinicians expressing concerns about the long-term safety of certain phosphate binders ⁽²³⁾. Strategies aimed at improving provider attitudes, such as continuing medical education on the latest evidence and guidelines, are crucial for aligning practices with the evolving landscape of CKD management.

5. Practices Related to Phosphate Binders

5.1 Patient Adherence: Patient adherence to prescribed phosphate binder regimens is a critical factor in achieving therapeutic goals ⁽²³⁾. Recent research indicates various barriers to adherence, including medication cost, complexity of dosing schedules, and the burden of managing multiple medications in the context of CKD ⁽²⁴⁾. Adherence enhancement strategies, such as simplified dosing regimens and patient education programs, have shown promise in improving adherence rates ⁽²⁵⁾. Addressing these barriers through patient-centered approaches is essential for optimizing treatment outcomes.

5.2 Healthcare Provider Practices: Healthcare providers' practices in monitoring and follow-up are integral components of successful phosphate binder management ⁽²⁶⁾. Studies highlight the importance of regular assessments of serum phosphate levels and adjustments to treatment plans based on individual patient responses ⁽²⁷⁾. Multidisciplinary approaches involving collaboration between nephrologists, dietitians, and pharmacists have proven effective in optimizing phosphate binder therapy and promoting patient well-being ⁽²⁸⁾.

6. Gaps and Challenges

6.1 Discrepancies in Knowledge: Despite efforts to improve knowledge, disparities persist among both patients and healthcare providers ⁽⁶⁾. Recent studies have identified gaps in understanding the long-term consequences of hyperphosphatemia and the potential impact of various phosphate binders on patient outcomes ⁽⁸⁾. Addressing these discrepancies is crucial for promoting informed decision-making and improving the overall quality of CKD care.

6.2 Addressing Patient Attitude Barriers: Challenges related to patient attitudes, including fears of side effects and reluctance to incorporate phosphate binders into daily routines, continue to be significant barriers to optimal treatment ⁽⁹⁾. Tailored interventions, such as individualized counseling and peer support programs, can play a pivotal role in overcoming these challenges and fostering a more positive attitude towards phosphate binder therapy.

6.3 Improving Prescribing Practices: Healthcare provider attitudes and prescribing practices exhibit variability, reflecting the evolving landscape of CKD management ⁽¹⁴⁾. Ongoing efforts to enhance provider education and awareness of recent research findings are essential for aligning prescribing practices with evidence-based guidelines ⁽¹⁵⁾. Bridging the gap between current practices and the latest evidence is imperative for achieving optimal outcomes in CKD patients receiving phosphate binders.

7. Future Directions

7.1 Patient Education Strategies: Future initiatives should focus on innovative patient education strategies to enhance awareness and understanding of phosphate binders ⁽²³⁾. Utilizing technology, such as mobile applications and interactive platforms, can facilitate ongoing patient engagement and provide real-time information tailored to individual needs ⁽²⁴⁾. The integration of patient-reported outcomes and preferences into educational programs can further personalize interventions and improve overall satisfaction with treatment.

7.2 Role of Technology in Adherence: Advancements in digital health solutions offer promising avenues for improving medication adherence ⁽²⁵⁾. Mobile health apps with reminders, educational modules, and feedback mechanisms can contribute to sustained patient engagement and adherence ⁽²⁶⁾. Exploring the integration of wearable devices and telehealth platforms may provide additional opportunities to monitor and support patients in managing their phosphate binder regimens effectively.

7.3 Collaborative Care Models: The future of phosphate binder management in CKD may benefit from enhanced collaborative care models ⁽²⁷⁾. Establishing closer collaboration between nephrologists, pharmacists, dietitians, and primary care providers can ensure comprehensive patient care ⁽²⁸⁾. Interdisciplinary care teams can collectively address knowledge gaps, streamline communication, and implement standardized protocols to optimize the prescription and monitoring of phosphate binders.

8. Conclusion

8.1 Summary of Findings: This comprehensive review has highlighted the intricate interplay of knowledge, attitude, and practices concerning phosphate binders in the management of chronic kidney disease ⁽¹⁾. Examining the mechanisms of action, the importance of these agents in CKD management, and the distinct types of phosphate binders has provided a foundational understanding of their role in clinical practice ^(3,4).

8.2 Implications for Clinical Practice: The review underscores the need for targeted interventions to address gaps in patient and healthcare provider knowledge, enhance positive attitudes, and improve adherence to phosphate binder regimens ⁽¹⁰⁾. Recognizing the challenges associated with prescribing practices and patient attitudes can guide the development of tailored strategies for optimizing phosphate binder therapy in CKD ⁽¹³⁾.

8.3 Recommendations for Future Research: Future research should prioritize the development and evaluation of innovative patient education strategies, explore the integration of technology in improving adherence, and further investigate collaborative care models to enhance overall patient outcomes ⁽¹⁸⁾. Investigating the impact of these interventions on long-term clinical outcomes and quality of life will contribute to the evolving landscape of CKD management ⁽²⁰⁾.

In conclusion, by bridging knowledge gaps, fostering positive attitudes, and refining clinical practices, the management of phosphate binders in CKD can be optimized, ultimately improving patient outcomes and the overall quality of care. Continuous efforts in research, education, and technology integration are essential for advancing the field and ensuring the best possible outcomes for individuals with CKD.

References

1. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. *JAMA*. 2015;313(8):837-846.
2. Kestenbaum B. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment. *Semin Dial*. 2006;19(4):273-279.
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. *Am J Kidney Dis*. 1998;31(4):607-617.
4. Isakova T, Barchi-Chung A, Enfield G, et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. *Clin J Am Soc Nephrol*. 2013;8(6):1009-1018.
5. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. *Lancet*. 2013;382(9900):1268-1277.
6. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*. 2006;69(11):1945-1953.
7. Levey AS, Inker LA, Matsushita K, et al. GFR decline as an endpoint for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. *Am J Kidney Dis*. 2014;64(6):821-835.
8. Fishbane S, Mathew A, Vaziri ND. Iron toxicity: relevance for dialysis patients. *Nephrol Dial Transplant*. 2014;29(2):255-259.
9. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. *Clin J Am Soc Nephrol*. 2009;4(6):1089-1096.
10. Mariano L, Valdez J, Lee J, et al. Impact of patient education on chronic kidney disease-mineral and bone disorder knowledge and self-management practices. *Nephrol Nurs J*. 2016;43(2):147-151.
11. Mathew AT, Strippoli GF, Ruospo M, Fishbane S. Reducing phosphorus content of oral drugs: a simple and cost-saving method for controlling hyperphosphatemia in hemodialysis patients. *J Ren Nutr*. 2012;22(3):422-426.
12. Gorostidi M, Sánchez-Martínez M, Ruilope LM, Graciani A, de la Cruz JJ, Santamaría R, et al. Control of mineral metabolism and bone disease in haemodialysis patients: a cross-sectional study. *Nephrol Dial Transplant*. 2013;28(4): 1033-1042.
13. Karamanidou C, Weinman J, Horne R. Improving haemodialysis patients' understanding of phosphate-binding medication: a pilot study of a psycho-educational intervention designed to change patients' perceptions of the problem and treatment. *Br J Health Psychol*. 2014;19(3): 563-579.

14. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. *N Engl J Med*. 2008;359(6):584-592.
15. Tomasello S, Dhupar R, Antonelli G, et al. Patients' knowledge of phosphorus in their diet: why is it important? *J Ren Nutr*. 2018;28(1):59-63.
16. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. *J Am Soc Nephrol*. 2012;23(8): 1407-1415.
17. Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. *Clin J Am Soc Nephrol*. 2012;7(3):487-493.
18. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. *J Am Soc Nephrol*. 2005;16(3):800-807.
19. Toussaint ND, Pedagogos E, Lau KK, et al. Phosphate kinetics during hemodialysis: Evidence for biphasic regulation. *J Am Soc Nephrol*. 2006;17(10):2930-2940.
20. Johnson RJ, Hill GS, Maroni BJ, et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. *Am J Med*. 1992;93(6):633-640.
21. Smith DH, Gullion CM, Nichols G, et al. Predicting costs of care in CKD: the role of comorbid conditions. *Am J Kidney Dis*. 2008;52(5): 806-813.
22. Ramirez SP, McClellan W, Port FK, Hsu SI. Risk factors for proteinuria in a large, multiracial, southeast Asian population. *J Am Soc Nephrol*. 2002;13(7):1907-1917.
23. Brown E, Wainwright E, Glynn LG, et al. Models of general practitioner consultation influenced by long term conditions in high-income countries: a systematic review. *BMC Fam Pract*. 2016;17(1): 1-14.
24. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. *PLoS One*. 2016;11(7):e0158765.
25. Suttorp MM, Siegerink B, Jager KJ, Zoccali C, Dekker FW. Graphical presentation of confounding in directed acyclic graphs. *Nephrol Dial Transplant*. 2015;30(9):1418-1423.
26. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. *PLoS One*. 2016;11(7):e0158765.
27. Brown E, Wainwright E, Glynn LG, et al. Models of general practitioner consultation influenced by long term conditions in high-income countries: a systematic review. *BMC Fam Pract*. 2016;17(1): 1-14.
28. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. *J Am Soc Nephrol*. 2004;15(8):2208-2218.